Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Seamless Therapeutics | Dresden | Seed | $12.6M | 2024-04-23 |
| Kynexis | Naarden | Series A | $112.3M | 2026-08-19 |
| Beacon Therapeutics | Alachua | Series C | $75.0M | 2026-01-08 |
| AIRNA | Cambridge | Series B | $155.0M | 2025-04-01 |
| Marea Therapeutics | San Francisco | Series B | $190.0M | 2024-06-18 |
| SynOx Therapeutics | Dublin | Series B | $92.0M | 2024-10-30 |
| VectorY | Amsterdam | Series A | $138.0M | 2023-11-13 |
| Calluna Pharma | Oslo | Series A | $81.4M | 2024-01-23 |
8 rows of the CSV in 5 of its 18 columns.
- The 25 Forbion Capital Partners portfolio companies have raised $3.3B in total.
- 2 of them closed their most recent round in the last 12 months, $187.3M combined.
- The largest of those rounds is Kynexis' $112.3M Series A, dated August 2026.
- RA Capital Management is an investor in 3 of them, more than any other fund.
- Biotech is the most common sector, with 23 companies (92%).
- 56% were founded in 2020 or later; the median founding year is 2020.
- The most common team size is 11 to 50 employees (68% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
14 of 25| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Kynexis | Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. | Biotech | Naarden, The Netherlands | Series A | $112.3M | 2026-08-19 | $173.3M | Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures | 11 to 50 | 2023 |
| Beacon Therapeutics | Beacon Therapeutics develops treatments to preserve and restore vision for eye diseases. | Biotech | Alachua, United States | Series C | $75.0M | 2026-01-08 | $365.1M | Oxford Science Enterprises, Forbion Capital Partners, Advent Life Sciences +1 | 101 to 250 | 2023 |
| AIRNA | AIRNA develops RNA editing technologies to create medicines for various diseases. | Biotech | Cambridge, United States | Series B | $155.0M | 2025-04-01 | $245.0M | ARCH Venture Partners, Alexandria Venture Investments, Forbion Capital Partners +2 | 51 to 100 | 2021 |
| Noema Pharma | Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. | Biotech | Basel, Switzerland | Series B | $147.2M | 2024-12-11 | $316.5M | Polaris Partners, Sofinnova Partners, Invus +2 | 11 to 50 | 2019 |
| SynOx Therapeutics | SynOx Therapeutics is a biotechnology company developing treatments for diffuse tenosynovial giant cell tumors. | Biotech | Dublin, Ireland | Series B | $92.0M | 2024-10-30 | $245.9M | Forbion Capital Partners, Gimv, Hercules Capital +2 | 1 to 10 | 2020 |
| Solasta Bio | Solasta Bio develops environmentally friendly crop protection products. | Biotech | Glasgow, United Kingdom | Series A | $14.0M | 2024-09-11 | Scottish Enterprise, Future Planet Capital, Forbion Capital Partners | 11 to 50 | 2020 | |
| CatalYm | CatalYm develops immunotherapies to treat cancer. | Biotech | Planegg, Germany | Series D | $150.0M | 2024-07-16 | $260.9M | Bayern Kapital, Forbion Capital Partners, Novartis Venture Fund +1 | 11 to 50 | 2016 |
| Progentos Therapeutics | Progentos Therapeutics develops a multiple sclerosis treatment that stimulates the body's natural repair mechanisms. | Biotech | Watertown, United States | Series A | $65.0M | 2024-05-14 | $65.0M | Forbion Capital Partners, Dolby Family Ventures, Alta Partners +2 | 11 to 50 | 2023 |
| Calluna Pharma | Calluna Pharma develops first-in-class therapies that target chronic inflammation and fibrosis at their source. | Biotech | Oslo, Norway | Series A | $81.4M | 2024-01-23 | Forbion Capital Partners, Investinor, Sarsia +1 | 11 to 50 | 2024 | |
| VectorY | VectorY develops gene therapies for central nervous system, somatic, and muscle diseases. | Biotech | Amsterdam, The Netherlands | Series A | $138.0M | 2023-11-13 | $175.6M | Insight Partners, Benhamou Global Ventures, Forbion Capital Partners +2 | 51 to 100 | 2020 |
| Aiolos Bio | Aiolos Bio is a biotech company developing therapies for respiratory diseases and immune conditions. | Biotech | San Francisco, United States | Series A | $245.0M | 2023-10-24 | $245.0M | RA Capital Management, Atlas Venture, Forbion Capital Partners +2 | 11 to 50 | 2023 |
| Rampart Bioscience | Rampart Bioscience develops gene medicines for long-lasting treatment of diverse diseases. | Biotech | La Jolla, United States | Series A | $85.0M | 2023-10-24 | $85.0M | RA Capital Management, OrbiMed, Forbion Capital Partners +1 | 11 to 50 | 2019 |
| Mariana Oncology | Mariana Oncology conducts biotechnology research in the oncology field. | Biotech | Watertown, United States | Series B | $175.0M | 2023-09-07 | $250.0M | RA Capital Management, Forbion Capital Partners, Surveyor Capital +1 | 11 to 50 | 2021 |
| Roche Glycart | Roche Glycart researches, develops, and commercializes antibody-based biotechnology products. | Biotech | Schlieren, Switzerland | Series A | $13.6M | 2003-11-26 | $13.6M | Forbion Capital Partners, Novartis Venture Fund, BioMedPartners +1 | 101 to 250 | 2000 |
Table 1. Forbion Capital Partners portfolio companies: the 14 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 25.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kynexis | Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. | Biotech | Naarden, The Netherlands | Series A | $112.3M | 2026-08-19 | $173.3M | Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures | 11 to 50 | 2023 |
| 2 | Beacon Therapeutics | Beacon Therapeutics develops treatments to preserve and restore vision for eye diseases. | Biotech | Alachua, United States | Series C | $75.0M | 2026-01-08 | $365.1M | Oxford Science Enterprises, Forbion Capital Partners, Advent Life Sciences +1 | 101 to 250 | 2023 |
Table 2. Forbion Capital Partners portfolio companies: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Management | Startup incubator | Boston, United States | 3 | 12% | ||
| 2 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 3 | 12% | ||
| 3 | Perceptive Advisors | Hedge fund | New York, United States | 2 | 8% | ||
| 4 | Surveyor Capital | Hedge fund | Chicago, United States | 2 | 8% | ||
| 5 | Bioqube Ventures | Venture capital firm | Hasselt, Belgium | 2 | 8% | ||
| 6 | Sofinnova Partners | Venture capital firm | Paris, France | 2 | 8% | ||
| 7 | ABN AMRO Fund | Corporate venture arm | Amsterdam, The Netherlands | 2 | 8% | ||
| 8 | Gilde Healthcare | Private equity firm | Utrecht, The Netherlands | 2 | 8% | ||
| 9 | GO-Bio | Government investment office | Berlin, Germany | 1 | 4% | ||
| 10 | Wellington Partners | Venture capital firm | Munich, Germany | 1 | 4% | ||
| 11 | Sunstone Life Science Ventures | Micro VC fund | Copenhagen, Denmark | 1 | 4% | 1 | Kynexis |
| 12 | Ysios Capital | Venture capital firm | San Sebastian, Spain | 1 | 4% | 1 | Kynexis |
| 13 | TCG Crossover | Hedge fund | Palo Alto, United States | 1 | 4% | 1 | Beacon Therapeutics |
| 14 | Advent Life Sciences | Venture capital firm | London, United Kingdom | 1 | 4% | 1 | Beacon Therapeutics |
| 15 | Oxford Science Enterprises | Venture capital firm | Oxford, United Kingdom | 1 | 4% | 1 | Beacon Therapeutics |
Table 3. Forbion Capital Partners portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 23 | 92% | $3.2B |
| Health care | 22 | 88% | $3.0B |
| Software | 2 | 8% | $68.3M |
Table 4. Forbion Capital Partners portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Forbion Capital Partners portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 9 | 36% |
| Germany | 4 | 16% |
| United Kingdom | 4 | 16% |
| The Netherlands | 3 | 12% |
| Switzerland | 2 | 8% |
| Ireland | 1 | 4% |
| Norway | 1 | 4% |
| Spain | 1 | 4% |
Table 6. Forbion Capital Partners portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Forbion Capital Partners portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| August 2026 | 1 | 50% | $112.3M |
| January 2026 | 1 | 50% | $75.0M |
Table 8. Forbion Capital Partners portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 2 | 8% | $187.3M |
| 2025 | 1 | 4% | $155.0M |
| 2024 | 12 | 48% | $1.1B |
| 2023 | 5 | 20% | $651.5M |
| 2021 | 1 | 4% | $35.0M |
| 2016 | 1 | 4% | $24.8M |
Table 9. Forbion Capital Partners portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 5 | 20% |
| 2020 to 2022 | 9 | 36% |
| 2015 to 2019 | 5 | 20% |
| 2010 to 2014 | 2 | 8% |
| Before 2010 | 4 | 16% |
Table 10. Forbion Capital Partners portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 3 | 12% |
| 11 to 50 | 17 | 68% |
| 51 to 100 | 2 | 8% |
| 101 to 250 | 3 | 12% |
Table 11. Forbion Capital Partners portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Forbion Capital Partners is recorded as one of its investors. On 16 November 2026 that is 25 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 14 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 25 rows: 0 have no round amount, 0 no city and 1 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many Forbion Capital Partners portfolio companies are on the list?
- 25, in the file dated 16 November 2026. 2 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 25 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.